Reed et al v. GlaxoSmithKline, LLC
| Agee Adams Reed and Jane Bishop Reed |
| GlaxoSmithKline, LLC |
| 1:2019cv11141 |
| May 20, 2019 |
| US District Court for the District of Massachusetts |
| F Dennis Saylor |
| Personal Injury: Health Care/Pharmaceutical Personal Injury Product Liability |
| 28 U.S.C. ยง 1332 |
| Plaintiff |
Docket Report
RSS Track this Docket
This docket was last retrieved on July 16, 2019. A more recent docket listing may be available from PACER.
| Document Text |
|---|
| Filing 11 Judge F. Dennis Saylor, IV: ORDER entered. MDL Order No. 35Associated Cases: 1:15-md-02657-FDS et al.(McDonagh, Christina) |
| Filing 10 Electronic Clerk's Notes for proceedings held before Judge F. Dennis Saylor, IV: Status Conference held on 7/10/2019. (1) The Court heard updates on the current total of federal and state filings. (2) The Court heard updates on Phase 5 discovery.(3) A colloquy was held about scheduling issues in Rodriguez v. GSK, Case No. 1:15-cv-13762, the first case selected for trial. The Court will postpone the 9/16/2019 trial date in order to address the issue of federal preemption. Trial counsel are directed to file statements of their availability in late 2019 and early 2020 with the Court by 7/17/2019 so that the trial can be rescheduled. (4) A colloquy was held about how the Court should proceed in light of the United States Supreme Courts recently issued decision in Merck Sharp & Dohme Corp. v. Albrecht. GSK will have until 7/18/2019 to file a renewed motion for summary judgment on the basis of preemption. Any oppositions must be filed within 45 days after service of the motion, and any replies must be filed within 14 days after service of the opposition. In addition, the parties will have until 7/24/2019 to file proposed language for a submission inviting the FDA to file an amicus brief in connection with the forthcoming motion.(5) The Court heard updates on plaintiffs motion to compel discovery from a GSK consultant.(6) The Court scheduled further status conferences for 8/14/2019; 9/18/2019; and 10/17/2019.(7) The Court heard argument on GSKs motions for summary judgment based on lack of general causation evidence and took the matters under advisement. (Court Reporter: Valerie OHara at vaohara@gmail.com.)(Attorneys present: Various) Associated Cases: 1:15-md-02657-FDS et al.(Bono, Christine) |
| Filing 9 NOTICE TO TELEPHONE PARTICIPANTS: Please use the following Participant line: (800) 459-5346 and Conference ID: Zofran for the Status Conference set for July 10, 2019 at 1:30 PM Associated Cases: 1:15-md-02657-FDS et al.(Bono, Christine) |
| Filing 8 Judge F. Dennis Saylor, IV: ORDER entered. MDL Order No. 34. ORDER FURTHER SUPPLEMENTING AND MODIFYING MDL ORDER NOS. 30 AND 31. Associated Cases: 1:15-md-02657-FDS et al.(Bono, Christine) |
| Filing 7 Electronic Clerk's Notes for proceedings held before Judge F. Dennis Saylor, IV: Status Conference held on 6/11/2019.(1) The Court heard updates on the current total of federal and state filings.(2) The Court heard updates on Phase 5 fact discovery. (3) The Court heard updates on Phase 5 expert discovery, including Magistrate Judge Dein's recently issued order on plaintiffs motions to compel in Fluth v. GSK, Case No. 1:17-cv-10066. (4) The Court heard updates on Phase 5, Group 1 trial selections, including Rodriguez v. GSK, Case No. 1:15-cv-13762, the first case selected for trial.(5) A colloquy was held about how the Court should proceed in light of the United States Supreme Court's recently issued decision in Merck Sharp & Dohme Corp. v. Albrecht. The parties will have until 7/1/2019 to file any additional briefing on the question of preemption, such as a renewed motion for summary judgment. Any oppositions will be due 7/9/2019. The Court will take the matter up at the 7/10/2019 status conference.(6) A colloquy was held about trial logistics and setting a timetable for further pretrial filings.(7) The Court heard updates on GSK's motion for summary judgment based on lack of general causation evidence, and a colloquy was held about filing logistics. (Court Reporter: Valerie OHara at vaohara@gmail.com.)(Attorneys present: Various) Associated Cases: 1:15-md-02657-FDS et al.(Pezzarossi, Lisa) |
| Filing 6 NOTICE of Appearance by Jennifer M. Stevenson on behalf of GlaxoSmithKline, LLC (Stevenson, Jennifer) |
| Filing 5 Summons Issued as to All Defendants. Counsel receiving this notice electronically should download this summons, complete one for each defendant and serve it in accordance with Fed.R.Civ.P. 4 and LR 4.1. Summons will be mailed to plaintiff(s) not receiving notice electronically for completion of service. (Vieira, Leonardo) |
| Filing 4 NOTICE OF MDL CASE OPENED, Direct file in the District of Massachusetts; Reed, et al v. GlaxoSmithKline, LLC. In Re: Zofran (Ondansetron) Products Liability Litigation, MDL 2657. (Finn, Mary) |
| Filing 3 ELECTRONIC NOTICE of Case Assignment. Judge F. Dennis Saylor, IV assigned to case. (Finn, Mary) |
Filing 2
General Order 09-1, dated January 6, 2009 regarding the E-Government Act and Personal Identifiers entered. (Vieira, Leonardo)
|
| Filing 1 COMPLAINT against GlaxoSmithKline, LLC (Fee Status: Paid in a member case) Short form complaint is filed as related to MDL: 2768 and the member case number is 1:19-cv-11141, filed by Agee Adams Reed, Jane Bishop Reed. (Attachments: #1 Category Form, #2 Civil Cover Sheet)(Millrood, Tobias) |
Access additional case information on PACER
Use the links below to access additional information about this case on the US Court's PACER system. A subscription to PACER is required.
Access this case on the Massachusetts District Court's Electronic Court Filings (ECF) System
- Search for Party Aliases
- Associated Cases
- Attorneys
- Case File Location
- Case Summary
- Docket Report
- History/Documents
- Parties
- Related Transactions
- Check Status
Disclaimer: Justia Dockets & Filings provides public litigation records from the federal appellate and district courts. These filings and docket sheets should not be considered findings of fact or liability, nor do they necessarily reflect the view of Justia.
